Predictors for Pulmonary Tuberculosis Outcome and Adverse Events in an Italian Referral Hospital: A Nine-Year Retrospective Study (2013-2021).
Journal
Annals of global health
ISSN: 2214-9996
Titre abrégé: Ann Glob Health
Pays: United States
ID NLM: 101620864
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
18
5
2022
pubmed:
19
5
2022
medline:
20
5
2022
Statut:
epublish
Résumé
The COVID-19 pandemic has undone years of progress in providing essential TB services and controlling the TB burden. Italy, a low TB burden country, has an incidence of 7.1 cases per 100,000 people. To control the TB spreading in Italy is critical to investigate the characteristics of patients with the worst outcomes and the highest risk of adverse events related to antituberculosis therapy. Therefore, we conducted a large retrospective study in TB patients admitted to the Clinic of Infectious Diseases University of Bari, Italy, in order to describe the clinical presentation and the factors associated with adverse events and outcomes. We retrospectively evaluated the patients admitted to the Clinic of Infectious Diseases from January 2013 to 15 December 2021. We stratified our cohort into two groups: <65 years of age and ≥65 years in order to assess any differences between the two groups. Two logistic regression models were implemented considering the dependent variables as: (I) the adverse events; and (II) the unsuccessful treatments. In total, 206 consecutive patients [60% (n = 124) M, median age 39 years, range 16-92] were diagnosed and admitted with TB at Clinic of Infectious Diseases. Of the whole sample, 151 (74%) were <65 years and 55 (26%) were ≥65. Statistically significant differences between the two groups were detected ( The pharmacological approach alone seems insufficient to treat and cure a disease whose ethiopathogenesis is not only due to the
Sections du résumé
Background
The COVID-19 pandemic has undone years of progress in providing essential TB services and controlling the TB burden. Italy, a low TB burden country, has an incidence of 7.1 cases per 100,000 people. To control the TB spreading in Italy is critical to investigate the characteristics of patients with the worst outcomes and the highest risk of adverse events related to antituberculosis therapy. Therefore, we conducted a large retrospective study in TB patients admitted to the Clinic of Infectious Diseases University of Bari, Italy, in order to describe the clinical presentation and the factors associated with adverse events and outcomes.
Methods
We retrospectively evaluated the patients admitted to the Clinic of Infectious Diseases from January 2013 to 15 December 2021. We stratified our cohort into two groups: <65 years of age and ≥65 years in order to assess any differences between the two groups. Two logistic regression models were implemented considering the dependent variables as: (I) the adverse events; and (II) the unsuccessful treatments.
Results
In total, 206 consecutive patients [60% (n = 124) M, median age 39 years, range 16-92] were diagnosed and admitted with TB at Clinic of Infectious Diseases. Of the whole sample, 151 (74%) were <65 years and 55 (26%) were ≥65. Statistically significant differences between the two groups were detected (
Conclusions
The pharmacological approach alone seems insufficient to treat and cure a disease whose ethiopathogenesis is not only due to the
Identifiants
pubmed: 35582409
doi: 10.5334/aogh.3677
pmc: PMC9053535
doi:
Substances chimiques
Antitubercular Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
26Informations de copyright
Copyright: © 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors have no competing interests to declare.
Références
Int J Epidemiol. 2020 Jun 1;49(3):776-785
pubmed: 32380550
J Clin Tuberc Other Mycobact Dis. 2020 Jan 07;18:100143
pubmed: 31956700
PLoS One. 2014 Apr 14;9(4):e94728
pubmed: 24733156
BMC Infect Dis. 2019 Mar 27;19(1):286
pubmed: 30917788
Tuberculosis (Edinb). 2017 Mar;103:44-51
pubmed: 28237033
Eur Respir J. 2019 Oct 31;54(4):
pubmed: 31413161
Int J Infect Dis. 2021 Dec;113 Suppl 1:S7-S12
pubmed: 33716195
Antibiotics (Basel). 2021 Mar 08;10(3):
pubmed: 33800406
Eur Respir J. 2020 Jul 9;56(1):
pubmed: 32444399
BMC Public Health. 2013 Feb 02;13:97
pubmed: 23374118
BMC Health Serv Res. 2020 Feb 3;20(1):83
pubmed: 32013962
Trop Med Infect Dis. 2021 Oct 15;6(4):
pubmed: 34698299
Eur Respir J. 2019 Dec 19;54(6):
pubmed: 31601711
Infect Dis Poverty. 2017 Jun 1;6(1):70
pubmed: 28569191
Exp Gerontol. 2018 May;105:32-39
pubmed: 29287772
Lancet Respir Med. 2020 Apr;8(4):383-394
pubmed: 32192585
Int J Tuberc Lung Dis. 2018 Dec 1;22(12):1495-1504
pubmed: 30606323
Clin Respir J. 2021 Jan;15(1):97-108
pubmed: 32949069
BMC Infect Dis. 2021 Oct 6;21(1):1038
pubmed: 34615474
Public Health. 2020 Mar;180:17-21
pubmed: 31837610
Ann Clin Microbiol Antimicrob. 2020 May 23;19(1):21
pubmed: 32446305
BMC Public Health. 2011 May 23;11:376
pubmed: 21605460
Travel Med Infect Dis. 2019 Jan - Feb;27:39-45
pubmed: 30347248
Isr J Health Policy Res. 2020 Aug 3;9(1):29
pubmed: 32741367
Lancet Glob Health. 2019 Jun;7(6):e707
pubmed: 31097272
Epidemiol Infect. 2017 May;145(7):1374-1381
pubmed: 28190404
Clin Microbiol Infect. 2017 Mar;23(3):141-146
pubmed: 27665703
BMC Infect Dis. 2018 Dec 20;18(1):690
pubmed: 30572830
Antibiotics (Basel). 2020 Aug 07;9(8):
pubmed: 32784552
BMC Infect Dis. 2020 Aug 24;20(1):622
pubmed: 32831044